Treatment Outcomes of Graded Dose of Empagliflozin in Type-2 Diabetes: A Real World Study

BACKGROUND: Costs are important cause of therapeutic noncompliance in type-2 diabetes mellitus (T2DM). Half-tablet empagliflozin (EMPA)-25 mg has lowest monthly cost among all EMPA preparations; data is unavailable on efficacy of half EMPA-25. This study compared real world weight loss and glycaemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutta, Deep, Sharma, Meha, Aggarwal, Sameer, Agarwal, Anshita, Dhall, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020632/
https://www.ncbi.nlm.nih.gov/pubmed/35313401
http://dx.doi.org/10.4103/aam.aam_69_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020632/
https://www.ncbi.nlm.nih.gov/pubmed/35313401
http://dx.doi.org/10.4103/aam.aam_69_20

Ejemplares similares